Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Intraoperative Esmolol in Mastectomies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, aged 18 to 75 years, electively scheduled to perform mastectomy in the Base Hospital of the Federal District;~* Physical State 1 or 2 the American Society of Anesthesiology (ASA);~Exclusion Criteria:~* Patients under the age of 18 years and above 75 years;~* Patients with unstable angina~* Patient with poorly controlled asthma~* Substance abuse~* Sinus bradycardia~* Heart failure, greater than first degree atrioventricular block~* Pregnant women~* Patients with allergy to dipyrone, morphine;~* Patients with chronic pain;~* Patients with severe hepatic disease;~* Patients with severe kidney disease;~* Patients with neurological diseases;~* Included patients in other clinical studies currently or in the past three months under general anesthesia;~* Patients who refuse to participate in the study;~* Any other condition that, in the opinion of the investigator, may pose a risk to the patient or interfere with the study objectives;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
- Esmolol group (Type: ACTIVE_COMPARATOR): Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).